Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
Holding SAVA?
Track your performance easily
SAVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.79 - $42.20
Previous Close$26.48
Volume7.44M
Average Volume (3M)1.77M
Market Cap
$1.27B
Enterprise Value$1.12B
Total Cash (Recent Filing)$148.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 04, 2025EPS Estimate
-$0.4Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding48,110,475
10 Day Avg. Volume1,615,254
30 Day Avg. Volume1,773,788
Standard Deviation0.62
R-Squared0.00238
Alpha0.17
Financial Highlights & Ratios
Price to Book (P/B)7.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda72.07
Forecast
1Y Price Target
$116.00Price Target Upside338.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Cassava Sciences News
Bulls Say, Bears Say
Bulls Say
Alzheimer's Treatment ProgressSimufilam has the potential to be the first drug to durably modify disease progression over a treatment period greater than six months in Alzheimer’s disease.
Clinical Trial AdvancementsThe Phase 3 studies have Special Protocol Assessment (SPA) with the FDA and are supported by positive Phase 2b results.
Regulatory ResolutionThe settlement with the U.S. Securities and Exchange Commission put behind any controversy that could be a significant long-term challenge to upside in Cassava stock.
Bears Say
Clinical TrialsFailure of clinical trials to prove efficacy poses a significant risk to the investment thesis.
Financial UncertaintyA $40M loss contingency was recorded due to the ongoing SEC investigation, reflecting financial uncertainty.
Regulatory ChallengesRegulatory requirements for additional clinical studies could delay progress and increase costs.
---
Ownership Overview
7.63% Insiders
8.22% Mutual Funds
8.84% Other Institutional Investors
64.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAVA FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $8.79 and its highest was $42.20 in the past 12 months.
What is Cassava Sciences’s market cap?
Currently, no data Available
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is Mar 04, 2025 which is in 97 days.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on Nov 07, 2024. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.73 by $0.15.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Undervalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate is -$0.4.
How many shares outstanding does Cassava Sciences have?
Cassava Sciences has 48,110,474 shares outstanding.
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.73. Following the earnings report the stock price went down -4.629%.
Which hedge fund is a major shareholder of Cassava Sciences?
Among the largest hedge funds holding Cassava Sciences’s share is Gallacher Capital Management LLC. It holds Cassava Sciences’s shares valued at 17M.
---
Cassava Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$116.00 (338.07% Upside)
$116.00 (338.07% Upside)
Blogger Sentiment
Bullish
SAVA Sentiment 81%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.43%
12-Months-Change
Fundamentals
Return on Equity
-10.98%
Trailing 12-Months
Asset Growth
29.69%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
---
SAVA Earnings Call
Q3 2024
0:00 / 0:00
---
SAVA Stock 12 Month Forecast
Average Price Target
$116.00
▲(338.07% Upside)
Technical Analysis
Best Analysts Covering SAVA
1 Year
1 Year Success Rate
9/31 ratings generated profit
1 Year Average Return
+23.06%
reiterated a buy rating 20 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 29.03% of your transactions generating a profit, with an average return of +23.06% per trade.
---